Qiliqiangxin Alleviates Imbalance of Inflammatory Cytokines in Patients with Dilated Cardiomyopathy:A Randomized Controlled Trial

扫码查看

原文链接

NETL
NSTL
万方数据

外文摘要：Objective:Qiliqiangxin(QLQX)capsule,a traditional Chinese medicine used for treating heart failure(HF),can modulate inflammatory cytokines in rats with myocardial infarction.However,its immune-regulating effect on dilated cardiomyopathy(DCM)remains unknown.The aim of this study was to investigate whether QLQX has a unique regulatory role in the imbalance of pro-and anti-inflammatory cytokines in patients with DCM.Methods:The QLQX-DCM is a randomized,double-blind trial conducted at 24 tertiary hospitals in China.A total of 345 patients with newly diagnosed virus-induced DCM were randomly assigned to receive QLQX capsules or placebo while receiving optimal medical therapy for HF.The primary endpoints were changes in plasma inflammatory cytokines and improvements in left ventricular ejection fraction(LVEF)and left ventricular end-diastolic diameter(LVEDd)over the 12-month treatment.Results:At the 12-month follow-up,the levels of IFN-γ,1L-17,TNF-α,and IL-4 decreased significantly,while the level of IL-10 increased in both groups compared with baselines(all P＜0.0001).Furthermore,these changes,coupled with improvements in LVEF,NT-proBNP and New York Heart Association(NYHA)functional classification,excluding the LVEDd in the QLQX group,were greater than those in the placebo group(all P＜0.001).Additionally,compared with placebo,QLQX treatment also reduced all-cause mortality and rehospitalization rates by 2.17％and 2.28％,respectively,but the difference was not statistically significant.Conclusion:QLQX has the potential to alleviate the imbalance of inflammatory cytokines in patients with DCM,potentially leading to further improvements in cardiac function when combined with anti-HF standard medications.

外文关键词：

Qiliqiangxin capsuledilated cardiomyopathyinflammatory cytokinescardiac functionrandomized controlled trial

作者：

Yu-hua LIAO、Jing YUAN、Xue-juan JIN、Ying-zhen YANG、Zhao-hui WANG、Miao YU、Gang TIAN、De-chao ZHAO、Bin LI、Wei-feng WU、Rui-zhen CHEN、Hong-yan HAN、Dongjie XU、Jin WEI、Hai-tao YUAN、on behalf of the Chinese Myocarditis & Cardiomyopathy Cooperation Group

展开 >

作者单位：

Department of Cardiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China

Hubei Key Laboratory of Biological Targeted Therapy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China

Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China

Department of Cardiology,Zhongshan Hospital,Fudan University,Shanghai 200000,China

Department of Cardiology,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China

Department of Cardiology,The First Affiliated Hospital of Harbin Medical University,Harbin 150001,China

Department of Cardiology,Xiangyang Central Hospital,Xiangyang 441021,China

Department of Cardiology,The First Affiliated Hospital of Guangxi Medical University,Nanling 530021,China

Department of Cardiology,Tianyou Hospital,Wuhan University of Science and Technology,Wuhan 430064,China

Department of Cardiology,The First Affiliated Hospital of Nanjing Medical University Nanjing 210029,China

Department of Cardiology,The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710004,China

Department of Cardiology,Shandong Provincial People's Hospital,Jinan 250021,China

展开 >

出版年：

2024

DOI：

10.1007/s11596-024-2916-9

当代医学科学(英文)

华中科技大学同济医学院

当代医学科学(英文)

影响因子：0.748

ISSN：2096-5230

年,卷(期)：2024.44(6)